MYBPC3 and cardiomyopathy: We report a novel approach to discover two distinct classes of compounds that affect the binding of the N-terminal cC0-C2 fragment of cMyBP-C to actin and/or myosin, with the aim of finding improved therapies for HF and cardiomyopathy patients.